U.S. Markets closed

DermTech, Inc. (DMTK.MX)

Mexico - Mexico Delayed Price. Currency in MXN
Add to watchlist
670.00-30.02 (-4.29%)
At close: 1:04PM CDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close700.02
Bid610.00 x N/A
Ask739.90 x N/A
Day's Range670.00 - 670.00
52 Week Range599.58 - 1,500.00
Avg. Volume1,822
Market Cap19.779B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-43.16
Earnings DateMay 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    DermTech Sponsors San Diego Open; Partners with Tennis Pro Brandon Nakashima to Raise Awareness for Sun Safety

    LA JOLLA, Calif., September 27, 2021--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the sponsorship of the San Diego Open, an ATP 250 tournament, and a partnership with San Diego native and tennis pro Brandon Nakashima. The sponsorships further represent DermTech’s commitment to the San Diego community and goal of raising awareness on the importance of sun safety and skin checks to

  • Motley Fool

    3 Stocks That Could Double Your Money Sooner Than You Think

    It will probably take IIP longer to double again, but achieving the goal within the next three to five years seems quite attainable. IIP is a real estate investment trust (REIT) that's focused on the medical cannabis market. The company has generated its growth so far by buying properties from medical cannabis operators, then leasing those properties back to the operators.

  • Motley Fool

    Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 Years

    The iShares Biotechnology ETF (NASDAQ: IBB) has delivered a solid double-digit percentage gain. Meanwhile, the SPDR S&P Biotech ETF (NYSEMKT: XBI) is in negative territory year to date and is close to 25% below its February highs. The key to success for the iShares Biotechnology ETF (IBB) has been Moderna (NASDAQ: MRNA).